Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Sumitomo Mitsui Trust Group Inc. lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 20.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor ...

Based on pharmacokinetic studies demonstrating comparable epinephrine exposure to intramuscular injections, this expansion follows ... Drug Application for a higher dose regimen of nusinersen ...

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

The cash injection comes as Biogen has been hit hard ... as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars ...

The quick uptake has come despite the established presence on the market of Biogen’s Spinraza (nusinersen), an antisense drug given by injection into the spine, which became the first treatment ...